RxDoctor Payments Data

Linda Arnold

Family · Lancaster, PANPI 1942791918

Payments from drug & device makers

$540in general payments, 2019–2025

Across 29 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$341
  • Mylan Specialty L.p.$51
  • Lilly USA, LLC$32
  • GSK$26
  • CMP Pharma, Inc.$25
  • Otsuka America Pharmaceutical, Inc.$23
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$540100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$540 in reported general payments places this provider in the 60th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$94,191
Medicare patients
194
Services billed
1,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide94$80,068
RexultiBrexpiprazole101$36,951
EliquisApixaban236$35,438
CreonLipase/Protease/Amylase69$29,886
XareltoRivaroxaban134$19,195
RestasisCyclosporine11$7,546
Spiriva RespimatTiotropium Bromide13$7,295
JardianceEmpagliflozin46$7,128
EntrestoSacubitril/Valsartan52$4,568
Atorvastatin Calcium446$3,688
Oseltamivir Phosphate39$2,918
Midodrine Hcl79$2,407
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$2,271
Gabapentin232$1,890
Amiodarone Hcl128$1,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$32$80,06894 claims
AbbVieCreon, Restasis$20$37,43380 claims
Otsuka America Pharmaceutical, Inc.Rexulti$23$36,951101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,717 family providers in Pennsylvania.

Other family in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →